Clinical Trials
14 trialsNCT03280563 2025-11-10
MORPHEUS HR+BC
Hoffmann-La Roche
Phase 1/2 Completed
NCT02708680 2024-12-04
Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
Syndax Pharmaceuticals
Phase 1/2 Completed
NCT00828854 2022-06-30
Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing
Syndax Pharmaceuticals
Phase 2 Completed
NCT02623751 2022-06-21
Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer
Kyowa Kirin Co., Ltd.
Phase 1 Completed
NCT03291886 2022-06-21
Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT00754312 2022-06-06
A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer
Syndax Pharmaceuticals
Phase 1 Terminated
NCT00676663 2022-05-11
ENCORE301
Syndax Pharmaceuticals
Phase 2 Completed
NCT02897778 2022-04-28
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
Syndax Pharmaceuticals
Phase 1 Completed
NCT02909452 2022-01-25
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Syndax Pharmaceuticals
Phase 1 Completed
NCT02820961 2021-12-15
Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer
Syndax Pharmaceuticals
Phase 1 Completed
NCT01594398 2021-11-19
ENCORE110
Syndax Pharmaceuticals
Phase 1 Completed
NCT03538171 2021-07-09
Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer
Taizhou EOC Pharma Co., Ltd.
Phase 3 Unknown
NCT02833155 2019-05-07
Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer
Taizhou EOC Pharma Co., Ltd.
Phase 1 Completed
NCT02115594 2014-10-08
ENCORE305
Syndax Pharmaceuticals
Phase 2 Withdrawn